AUSTRALIANS with an aggressive form of lung cancer most common in non-smokers will now have affordable access to the first medicine to target the underlying cause of their disease.
Johnson & Johnson's bispecific antibody IV infusion Rybrevant (amivantamab) is now available through the Pharmaceutical Benefits Scheme (PBS) for people with locally advanced or metastatic non-small cell lung cancer caused by changes (Exon-20 insertion alterations) in the epidermal growth factor receptor gene.
Up to now, these patients, who tend to be younger than other lung cancer patients, paid around $7,400 per script and had limited options available via the PBS, and none for their cancer specifically.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 May 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 May 25
